MedTrace Logo

Desvenlafaxine for Treatment of Hot Flashes in Women With Breast Cancer Taking Tamoxifen

NCT02819921 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2019-09-20

No results posted yet for this study

Summary

This study is a randomized, placebo-controlled study of desvenlafaxine versus placebo. The purpose of this study is to determine if desvenlafaxine was effective in decreasing the frequency and severity of hot flashes in breast cancer patients taking tamoxifen.

Conditions

Interventions

DRUG

Desvenlafaxine succinate 100mg

Pristiq 100mg

DRUG

Desvenlafaxine succinate 50mg

Pristiq 50mg

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Seoul National University Bundang Hospital

    collaborator OTHER

  • Korea Cancer Center Hospital

    collaborator OTHER

  • Pfizer

    collaborator INDUSTRY

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Bong-Jin Hahm, M.D., Ph.D. · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-10
Primary Completion
2019-03-15
Completion
2019-06-15

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02819921 on ClinicalTrials.gov